2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Pathology, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Bleeding and Clotting, Bleeding Disorders, Thromboembolism, Thrombotic Disorders, VWD, Immunology, Autoimmune Disorders, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

1308 Polyphosphate: An energy source locked as polymer in endothelial cells is released by tissue-nonspecific alkaline phosphatase

Upendra Kumar Singh, PhD, Paresh P Kulkarni, MBBS, MD, PhD2, Bhagwati Joshi, PhD3, Katarzyna Bialkowska, PhD4, Keith McCrae, MD5
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States

INTRODUCTION: Polyphosphate (polyP) is an energy-rich linear polymer of inorganic phosphate monomers linked by high-energy bonds and known for its ability to stimulate FXII activation and enhance coagulation. In microorganisms it serves as a reservoir for phosphate and ATP, but in mammalian cells its metabolic role is poorly understood. polyP localizes to mitochondria and its loss impairs oxidative phosphorylation, yet how this reserve is accessed remains undefined. Tissue-nonspecific alkaline phosphatase (TNAP), an exophosphatase that hydrolyzes phosphate-rich substrates is expressed in human umbilical vein endothelial cells (HUVEC). We hypothesized that TNAP hydrolyzes polyP to liberate phosphate and sustain ATP for energy-intensive endothelial functions. This predicts that without TNAP energy remains locked into the polymer, thus polyP accumulates while ATP levels fall.

METHODS: HUVEC (passages 2-4) were transfected by electroporation with siRNA targeting TNAP or a scrambled (scRNA) control; TNAP knockdown was confirmed by qPCR and immunoblot. Angiogenesis was assessed using a Matrigel tube formation assay that was quantified by an automated Python/scikit-image pipeline with DAPI nuclei confirming cell number. Metabolic activity of HUVEC was measured by monitoring proliferation and viability and using IncuCyte live-cell imaging and colorimetric methods (MTS Assay). ATP content was measured by luciferase luminescence, and total polyP by exopolyphosphatase (PPx) digestion followed by measuring inorganic phosphate using malachite green. Bioenergetics were profiled on a Seahorse XF96 using a modified Mito Stress Test (oligomycin, FCCP, rotenone/antimycin A) with terminal 2-deoxyglucose; oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were normalized to the Hoechst nuclear signal. Migration of endothelial cells was assessed using a scratch-wound assay.

RESULTS: TNAP mRNA and protein were reduced by 89% (p=0.0007) and 75% (p<0.0001), respectively at 72 h by specific siRNA compared to scrambled control. TNAP silencing caused levels of total intracellular polyP to increase 1.9-fold. These results confirm TNAP as a determinant of the steady-state polyP level in these cells.

Cellular ATP content measured by luciferase luminescence was reduced significantly (41000±904 vs 21000±615, p < 0.0001) in TNAP-deficient cells compared to scrambled controls. Seahorse extracellular flux profiling using a modified Mito Stress Test revealed coordinate reductions in both oxygen consumption and extracellular acidification rates. Basal OCR was reduced in TNAP-deficiency (65±7.4 pmol/min versus scrambled control 90 ±9.2), while the basal ECAR for TNAP-KD was 26±2.3 mpH/min versus scrambled control 36± 2.7 mpH/min, suggesting that mitochondrial respiration and glycolysis declined in parallel. This pattern reflects a global downregulation of energy metabolism rather than a compensatory shift between pathways.

Functionally, TNAP silencing significantly impaired endothelial cell proliferation monitored by IncuCyte live-cell imaging (p<0.0001). In the Matrigel tube formation assay, TNAP-deficient HUVECs showed significant reductions in total tube length (100.1±5.1 vs 27.1±4.9, p<0.0001), number of branch points (138.2±24.9 vs 35.2±10.1, p=0.0022), and closed meshes (7.8±2.1 vs 1.9±1.5, p=0.0045) relative to scrambled controls (p<0.001). The migration of TNAP deficient cells after scratch wounding of monolayers was significantly reduced compared to scrambled controls.

CONCLUSIONS: In human endothelial cells, TNAP depletion elicits accumulation of intracellular polyP together with a decline in ATP and both mitochondrial and glycolytic flux, leading to impaired proliferation, migration and angiogenesis. The co-occurrence of these features points to an inability to mobilize stored polyP into usable energy. These findings suggest a defect in mobilizing stored polyP into usable energy, establishing TNAP as a mammalian polyP-catabolizing enzyme that couples endothelial polyP to ATP generation. These findings define a previously unrecognized bioenergetic role for TNAP in the endothelium.

Upendra Kumar Singh, PhD: No relevant conflicts of interest to declare.